RxDoctor Payments Data

Michael Moorehead

Optometrist · Hamilton, OHNPI 1659343317

Payments from drug & device makers

$1,375in general payments, 2019–2025

Across 36 payments — averaging $38.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$495
  • Bausch & Lomb Americas Inc.$262
  • Coopervision Inc.$163
  • Johnson & Johnson Vision Care, Inc.$145
  • Tarsus Pharmaceuticals, Inc.$139
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$79
  • plus $92 from 4 others

What the payments were for

  • Travel & lodging$44833%
  • Food & beverage$92767%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,375 in reported general payments places this provider in the 65th percentile of 1,995 optometrist providers in Ohio.

See all optometrist providers in Ohio

Medicare billing

Part B allowed, 2024
$61,083
Medicare patients
213
Services billed
775

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XdemvyLotilaner26$49,545
RestasisCyclosporine21$27,538
Brimonidine Tartrate15$3,138
Alphagan PBrimonidine Tartrate13$2,534
Travoprost11$2,353
Latanoprost144$1,271
Loteprednol Etabonate14$1,111
Dorzolamide Hcl21$695
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat24$218

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Tarsus Pharmaceuticals, Inc.Xdemvy$139$49,54526 claims
AbbVieRestasis, Alphagan P$22$30,07334 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$79$1,11114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,995 optometrist providers in Ohio.

Other optometrist in Hamilton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →